Since January 2020 Elsevier has created a COVID-19 resource centre with free information in English and Mandarin on the novel coronavirus COVID-19. The COVID-19 resource centre is hosted on Elsevier Connect, the company's public news and information website.

Elsevier hereby grants permission to make all its COVID-19-related research that is available on the COVID-19 resource centre - including this research content - immediately available in PubMed Central and other publicly funded repositories, such as the WHO COVID database with rights for unrestricted research re-use and analyses in any form or by any means with acknowledgement of the original source. These permissions are granted for free by Elsevier for as long as the COVID-19 resource centre remains active.
COVID-19 and Heart Transplantation. Initial Experience in a Tertiary Hospital

Raquel López-Vilella a, b, *, Ignacio Sánchez-Lázaro a, b, c, Víctor Donoso Trenado a, b, Silvia Lozano Edo b, Luis Martínez Dolz b, c, and Luis Almenar Bonet a, b, c, d

a Heart Failure and Transplant Unit, La Fe University and Polytechnic Hospital, Valencia, Spain; b Department of Cardiology, La Fe University and Polytechnic Hospital, Valencia, Spain; c Centro de Investigación Biomédica en Red de Enfermedades Cardiovasculares (CIBERCV), Instituto de Salud Carlos III, Madrid, Spain; and d Universidad de Valencia, Valencia, Spain

ABSTRACT

Background. Coronavirus disease 2019 (COVID-19) is a viral infectious disease caused by the severe acute respiratory syndrome coronavirus 2 virus that is affecting the entire world population. The objective of this study was to analyze the repercussion of the disease in a group of patients at risk such as heart transplant recipients.

Methods. From February 2020 to February 2021, heart transplant recipients diagnosed with COVID-19 were consecutively included. The total number of transplant recipients in outpatient follow-up at that time was 381. Three levels of infection were determined: group A: asymptomatic patients or with trivial symptoms without the need for hospital admission (6 patients); group B: patients admitted to the hospital for respiratory symptoms (12 patients); and group C: patients with severe symptoms and need for admission to the critical care unit (2 patients). At each risk level, medical performance was different: group A: close control, no therapeutic modification; group B: reduction of calcineurin inhibitor and substitution of mycophenolate mofetil for everolimus; group C: reduction of calcineurin inhibitor and withdrawal of mycophenolate mofetil.

Results. The prevalence of infection in the series was 5.2%. Most patients admitted had a pathologic chest x-ray with fever, cough, dyspnea, or vomiting. The change in immunosuppression performed in patients in group 2 was well tolerated and there was no graft rejection. Antiviral treatment was little used. However, boluses of steroids and some antibiotics were used frequently. The need for supplemental oxygen was 50% in group 2 and 100% in group 3.

Conclusions. A significant number of transplant recipients will be affected by COVID-19 (5.3%). Management of the infection will depend on the severity of the infection and must be based on a balance between reduction and adjustment of immunosuppression, strict control of the cardiologic situation, and treatment of the infection.

© 2021 Elsevier Inc. All rights reserved.
230 Park Avenue, New York, NY 10169

0041-1345/20
https://doi.org/10.1016/j.transproceed.2021.07.054

Transplantation Proceedings, 53, 2743−2746 (2021)

2743
MATERIALS AND METHODS

Heart transplant recipients diagnosed with COVID-19 were consecutively recruited from February 2020 to February 2021. The diagnosis could be accidental or due to infectious symptoms with positive polymerase chain reaction test. The total number of transplant recipients in outpatient follow-up at that time was 381. At the beginning of the pandemic, and considering the possibility and risk of infection in heart transplant recipients, the center’s heart transplant team drew up a protocol for therapeutic action according to the patient’s infectious situation. This protocol was carried out in all infected patients. Three levels of infection were determined: group A; asymptomatic patients or with trivial symptoms without the need for hospital admission (6 patients); group B: patients admitted to the hospital ward for respiratory symptoms (12 patients); group C; patients with severe symptoms and need for admission to the critical care unit (2 patients). At each level of risk, medical performance was different: group A: close control, no therapeutic modification; group B: reduction of calcineurin inhibitor (CNI) and substitution of mycophenolate mofetil (MMF) for everolimus (EVE); group C: reduction of CNI and withdrawal of MMF. In addition, patients were administered antiviral and general treatment corresponding to their clinical situation. Figure 1 shows the 3 established groups.

RESULTS

The prevalence of infection in the series was 5.2%. Most patients in the 3 groups were male. Those in higher risk groups were older. Most patients were admitted because of fever associated with cough, dyspnea, or vomiting. These symptoms, together with a pathologic chest x-ray, motivated the hospital admission. Electrocardiographic or arrhythmic abnormalities were observed in none of the 20 patients in the series (Table 1). The change in immunosuppression performed in patients in group 2 was well tolerated and there was no rejection. Antiviral treatment was little used. However, boluses of steroids and some antibiotics were used frequently. The need for supplemental oxygen was close to 50% in group 2 and 100% in group 3. The mean hospital stay was just over 2 weeks for hospitalized patients and almost 3 weeks for those admitted to critical care. The need for intubation was identified in a subgroup with a mortality of 100%, although there were only 2 cases.

DISCUSSION

Since the coronavirus pandemic began in Wuhan, China, this infection has spread throughout the worlds. The entire world population is susceptible to being infected, but there are some groups at higher risk owing to their immunosuppressive situation, including heart transplant recipients, in whom prevention of rejection during an infection continues to be a challenge. It is advisable to modify the immunosuppressive treatment according to the severity of the infection to try to protect heart transplant recipients. In this series, 3 risk groups were considered and it was found that patients with few symptoms have a good evolution; when respiratory symptoms (pneumonia) are present it is possible to control the infection with changes in immunosuppression. However, when the patient requires orotracheal intubation, the chances of survival are slim.

In this series, the prevalence of COVID-19 infection in heart transplant recipients was 5.2%. This coincides with the figures in the literature, although the prevalence is variable [1,2] in a country where the prevalence of infection in the general population is around 8% [3]. Most patients are men between the ages of 50 and 64 years, a profile similar to that described in other series of severe acute respiratory syndrome coronavirus 2—infected heart transplant recipients [2]. None of the cases occurred early after transplantation. The reason for consulting these patients was the same as in the general population and published series of transplants [2]; that is, the presentation of fever, dyspnea, cough, and/or vomiting. Thirty percent of patients (6) did not require hospital admission, 60% (12) required hospital admission without the need for critical care, and only 2 patients (10%) required admission to the critical care unit—a distribution similar to that observed in previous studies [1]. Immunosuppression is common in heart transplant recipients [4], with treatment including CNIs, MMF, and corticosteroids. The usual strategy followed in transplant recipients infected with COVID-19 is to reduce immunosuppression [2,5]. In this series, immunosuppression was not reduced in patients with a
Table 1. Clinical Profile and Therapeutic Approach According to Risk Group

|                          | Group A (n = 6) | Group B (n = 12) | Group C (n = 2) |
|--------------------------|----------------|------------------|----------------|
| Age (y)                  | 51.2 ± 17.5    | 59.9 ± 13.2      | 64.0 ± 14.6    |
| Male sex, n (%)          | 5 (83)         | 11 (92)          | 2 (100)        |
| Time since HTx (d)       | 2897 ± 2780    | 3777 ± 2462      | 1901 ± 2480    |
| Reason for admission, n (%) |              |                  |                |
| Fever (with cough, dyspnea, or vomiting) | 0 (0) | 11 (92) | 2 (100) |
| Dyspnea                  | 0 (0)          | 2 (17)           | 2 (100)        |
| Diarrhea                 | 0 (0)          | 2 (17)           | 0 (0)          |
| Chest x-ray, n (%)       | 0 (0)          | 10 (83)          | 2 (100)        |
| Normal                   | 6 (100)        | 2 (17)           | 0 (0)          |
| Pneumonia                | 0 (0)          | 0 (0)            | 0 (0)          |
| QT prolongation, n (%)   | 0 (0)          | 0 (0)            | 0 (0)          |
| Ventricular arrhythmias, n (%) | 0 (0) | 0 (0) | 0 (0) |
| Treatment during infection, n (%) |      |                  |                |
| Tacrolimus               | 4 (66)         | 5 (42)           | 1 (50)         |
| Cyclosporine             | 2 (33)         | 7 (58)           | 1 (50)         |
| MMF                      | 5 (83)         | 0 (0)            | 0 (0)          |
| Everolimus               | 1 (17)         | 12 (100)         | 0 (0)          |
| Deflazacort              | 6 (100)        | 12 (100)         | 2 (100)        |
| Antiviral treatment, n (%) |              |                  |                |
| Baricitinib              | 0 (0)          | 1 (8)            | 1 (50)         |
| Remdesivir               | 0 (0)          | 1 (8)            | 0 (0)          |
| Other treatments, n (%)  |              |                  |                |
| Lopinavir + ritonavir    | 0 (0)          | 1 (8)            | 0 (0)          |
| Chloroquine              | 0 (0)          | 4 (33)           | 0 (0)          |
| Azithromycin             | 0 (0)          | 6 (50)           | 0 (0)          |
| Steroid bowling          | 0 (0)          | 9 (75)           | 2 (100)        |
| Other antibiotics        | 0 (0)          | 9 (75)           | 2 (100)        |

Supplemental O2, n (%)

|                          | Group A (n = 6) | Group B (n = 12) | Group C (n = 2) |
|--------------------------|----------------|------------------|----------------|
| Nasal cannulas           | 0 (0)          | 4 (33)           | 0 (0)          |
| Venturi mask             | 0 (0)          | 2 (17)           | 0 (0)          |
| O2                       | 0 (0)          | 0 (0)            | 2 (100)        |
| Days of admission        | 0 (0)          | 18.2 ± 23.8      | 19.0 ± 20.1    |
| Exitus, n (%)            | 0 (0)          | 0 (0)            | 2 (100)        |

Data expressed as mean ± standard deviation or as otherwise noted. Two patients in group B died at the first and second month after infection owing to extra coronavirus disease causes (neoplasm of the colon and acute coronary syndrome).

HTx, heart transplant; MMF, mycophenolate mofetil; O2, oxygen; OI, orotracheal intubation.

CONCLUSIONS

A significant number of transplant recipients will be affected by COVID-19. Management of the infection will depend on the severity of the infection and should be based on a balance between reduction and adjustment of immunosuppression, strict control of the cardiologic situation, and treatment of the infection.

REFERENCES

[1] García-Cosío M, Flores Hernández M, Caravaca Pérez P, López-Medrano F, Arribas F, Delgado Jiménez J. Heart transplantation during the coronavirus disease 2019 pandemic: follow-up organization and characteristics of infected patients. Rev Esp Cardiol (Engl Ed) 2020;73:1077–80.

[2] Bottio T, Bagozzi L, Fiocco A, Nadali M, Caraffa R, Bifulco O. COVID-19 in heart transplant recipients: A Multicenter Analysis of the Northern Italian Outbreak. JACC Heart Fail 2021;9:52–61.

[3] Antonio L, Borraz M, Giménez M, Carrera P, González E, Ortiz C, et al. [Prevalence of SARS-CoV-2 coronavirus infection in patients and professional staff at a medium or long-stay hospital in Spain]. Rev Esp Geriatr Gerontol 2021;56:75–80 [in Spanish].

mild infection and the usual pattern was maintained, adjusting the CNI dose to the detected plasma levels. In group B, on the other hand, the CNI dose was reduced, as in other reported series [2], with the substitution of MMF for the mammalian target of rapamycin inhibitor EVE. This change was made because EVE reduces the risk of infection by other viruses, such as cytomegalovirus, by regulating factors involved in several cellular functions crucial for cytomegalovirus replication [6]. In contrast, MMF has traditionally been associated with viral infections and reactivations [7]. The change in immunosuppression was well tolerated. Only 2 of the 20 patients had poor evolution from the respiratory point of view, requiring orotracheal intubation. In this case, we opted for the suspension of MMF without substitution by EVE, reducing the dose of CNI, and maintaining or increasing if corticosteroid therapy was required. However, these 2 patients died. The mortality of the series was therefore 10%, lower than that reported in other registries [1,2], although the mortality in group 3 was 100% (2 patients).
[4] González-Vilchez F, Almenar Bonet L, Crespo-Leiro MG, Gómez-Bueno M, González-Costello J, Pérez-Villa F, et al. Spanish Heart Transplant Registry. 31th Official Report of the Heart Failure Association of the Spanish Society of Cardiology. Rev Esp Cardiol (Engl Ed) 2020;74:954–62.

[5] Sa MA, Ferna C, DeFilippis EM, Farr MA, Givertz MM. Challenges in heart transplantation in the era of COVID-19. Circulation 2020;73:2048–51.

[6] Tan L, Sato N, Shiraki A, Yanagita M, Yoshida Y, Takemura Y, et al. Everolimus delayed and suppressed cytomegalovirus DNA synthesis, spread of the infection, and alleviated cytomegalovirus infection. Antiviral Res 2019;162:30–8.

[7] Song AT, Abdala E, Bonazzi PR, Bacchella T, Machado MC. Does mycophenolate mofetil increase the risk of cytomegalovirus infection in solid organ transplant recipients? A mini-review. Braz J Infect Dis 2006;10:132–8.